Radiation meets immunotherapy – a perfect match in the era of combination therapy?

References

• Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. 2013. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res 1:280–284.
   PubMed Web of Science ®Google Scholar
• Akins EJ, Dubey P. 2008. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med 49:180s–195s.
   Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116.
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA. 2014. Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–997.
   PubMed Web of Science ®Google Scholar
• Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. 2013. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1:92–98.
   PubMed Web of Science ®Google Scholar
• Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C. 2014. Radiation- induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29:153–161.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Pardoll DM. 2013. Immune checkpoint inhibitors: Making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1:85–91.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. 2010. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J Clin Oncol 28: 4324–4332.
   PubMed Web of Science ®Google Scholar
• Burnette B, Fu YX, Weichselbaum RR. 2012. The confluence of radiotherapy and immunotherapy. Front Oncol 2:143.
   Google Scholar
• Cameron RB, Spiess PJ, Rosenberg SA. 1990. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 171:249–263.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. 2004. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328–4337.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. 2003. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170:6338–6347.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW. 2008a. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 57:1173–1183.
   PubMedGoogle Scholar
• Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW. 2008b. The use of chelated radionuclide (samarium-153- ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14:4241–4249.
   PubMedGoogle Scholar
• Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. 2005. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28:129–135.
   PubMed Web of Science ®Google Scholar
• Corso CD, Ali AN, Diaz R. 2011. Radiation-induced tumor neoantigens: Imaging and therapeutic implications. Am J Cancer Res 1:390–412.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. 2013. Breakthrough of the year 2013. Cancer immunotherapy. Science 342:1432–1433.
   Google Scholar
• Demaria S, Bhardwaj N, McBride WH, Formenti SC. 2005a. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63:655–666.
   PubMed Web of Science ®Google Scholar
• Demaria S, Vanpouille-Box C, Formenti SC, Adams S. 2013. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2:e25997.
   PubMed Web of Science ®Google Scholar
• Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC. 2014. The optimal partnership of radiation and immunotherapy: From preclinical studies to clinical translation. Radiat Res 182: 170–181.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. 2004. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862–870.
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. 2005b. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728–734.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. 2014. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687–695.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15: 5379–5388.
   PubMed Web of Science ®Google Scholar
• Diamond J, Vanpouille-Box C, Barcellos-Hoff MH, Formenti SC, Demaria S. 2013. The abscopal effect of local radiotherapy is induced by TGFβ blockade. J Immunother Cancer 1:P115.
   Google Scholar
• Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. 2011. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm 26:407–415.
   PubMed Web of Science ®Google Scholar
• Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, Felzmann T. 2007. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 9:755–770.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T. 2014. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 134:859–872.
   PubMed Web of Science ®Google Scholar
• Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. 2012. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo- adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 82:924–932.
   PubMed Web of Science ®Google Scholar
• Fishman M. 2014. Challenges facing the development of cancer vaccines. Methods Mol Biol 1139:543–553.
   PubMedGoogle Scholar
• Formenti SC, Demaria S. 2009. Systemic effects of local radiotherapy. Lancet Oncol 10:718–726.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. 2013. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 105:256–265.
   PubMed Web of Science ®Google Scholar
• Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, Gaipl US. 2014. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63:29–36.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. 2014. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5:403–416.
   PubMed Web of Science ®Google Scholar
• Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62:1462–1470.
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. 2004. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985–7994.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140:883–899.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D. 2011. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 11:1409–1418.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W. 2005. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11: 3353–3362.
   PubMed Web of Science ®Google Scholar
• Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. 2012. Radiotherapy promotes tumor-specific effector CD8 + T cells via dendritic cell activation. J Immunol 189:558–566.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646–674.
   PubMed Web of Science ®Google Scholar
• Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Chen C, Dahut W, Stadler W, Dipaola R, Stein M, Hodge J, Schlom J. 2012. Interim analysis of a phase II randomized clinical trial of samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol 30:Abstract 2526.
   Google Scholar
• Hodge JW, Sharp HJ, Gameiro SR. 2012. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 27:12–22.
   PubMed Web of Science ®Google Scholar
• Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. 2013. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73:2943–2948.
   PubMed Web of Science ®Google Scholar
• Ina Y, Sakai K. 2005. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: Analysis of immune cell populations and surface molecules. Int J Radiat Biol 81:721–729.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, June CH, Haas N, Vapiwala N. 2013. Radiation and immunotherapy: A synergistic combination. J Clin Invest 123: 2756–2763.
   PubMed Web of Science ®Google Scholar
• Kelderman S, Schumacher TN, Haanen JB. 2014. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 8: 1132–1139.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. 2013. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2:e25962.
   Google Scholar
• Kim R, Emi M, Tanabe K. 2006. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146:189–196.
   PubMed Web of Science ®Google Scholar
• Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schakel K, Garbi N, Jager D, Weitz J, Schmitz-Winnenthal H, Hammerling GJ, Beckhove P. 2013. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24:589–602.
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. 2012. In the field: Exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2:104.
   PubMedGoogle Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. 2008. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 14:5284–5291.
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. 2009. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: Changing strategies for cancer treatment. Blood 114:589–595.
   PubMed Web of Science ®Google Scholar
• Lim JY, Gerber SA, Murphy SP, Lord EM. 2014. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63: 259–271.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. 2011. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17:6958–6962.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Z. 2014. Molecular imaging in tracking tumor-specific Cytotoxic T Lymphocytes (CTLs). Theranostics 4:990–1001.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516–7523.
   PubMed Web of Science ®Google Scholar
• Matsumura S, Demaria S. 2010. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 173:418–425.
   PubMed Web of Science ®Google Scholar
• McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ, Iwamoto KS, Pervan M, Liao YP. 2004. A sense of danger from radiation. Radiat Res 162:1–19.
   PubMed Web of Science ®Google Scholar
• McDermott DF. 2007. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 13:716s–720s.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931.
   PubMed Web of Science ®Google Scholar
• Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. 2014. Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. J Immunother Cancer 2:14.
   PubMedGoogle Scholar
• Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. 2006. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259–1271.
   PubMed Web of Science ®Google Scholar
• Roses RE, Datta J, Czerniecki BJ. 2014. Radiation as immunomodulator: Implications for dendritic cell-based immunotherapy. Radiat Res 182:211–218.
   PubMedGoogle Scholar
• Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M. 2003. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma. J Exp Ther Oncol 3:161–168.
   PubMedGoogle Scholar
• Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M. 2004. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2. Eur J Cancer 40: 1412–1417.
   PubMedGoogle Scholar
• Schaue D, Ratikan JA, Iwamoto KS, McBride WH. 2012. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570.
   PubMed Web of Science ®Google Scholar
• Schwartz RN, Stover L, Dutcher J. 2002. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16:11–20.
   PubMed Web of Science ®Google Scholar
• Seung SK, Curti BD, Crittenden M, Urba W. 2012a. Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology 1:1645–1647.
   PubMed Web of Science ®Google Scholar
• Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ. 2012b. Phase 1 study of stereotactic body radiotherapy and interleukin-2 – tumor and immunological responses. Sci Transl Med 4:137ra74.
   Google Scholar
• Shen RN, Hornback NB, Shidnia H, Lu L, Montebello JF, Brahmi Z. 1988. A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. Radiat Res 114:354–360.
   PubMedGoogle Scholar
• Shigematsu A, Adachi Y, Koike-Kiriyama N, Suzuki Y, Iwasaki M, Koike Y, Nakano K, Mukaide H, Imamura M, Ikehara S. 2007. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. J Radiat Res 48:51–55.
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. 1991. Interleukin-2 toxicity. J Clin Oncol 9:694–704.
   PubMed Web of Science ®Google Scholar
• Slovin S, Beer T, Higano CS, Tejwani S, Hamid O, Picus J, Harzstark A, Scher HI, Lan Z, Lowy I. 2009. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 27: Abstract 5138.
   PubMedGoogle Scholar
• Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. 2013. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann Oncol 24:1813–1821.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
   PubMed Web of Science ®Google Scholar
• Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. 2014. Unlocking the combination: Potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 182:126–138.
   PubMed Web of Science ®Google Scholar
• Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. 2014. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 88:1188–1195.
   PubMedGoogle Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. 2013. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133.
   PubMed Web of Science ®Google Scholar
• Youn H, Hong KJ. 2012. In vivo non invasive molecular imaging for immune cell tracking in small animals. Immune Netw 12:223–229.
   PubMedGoogle Scholar